Drug intelligence / Profile preview

regn13335

Development stage: Phase 2
Lead developer: Regeneron Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

REGN13335 is a humanized immunoglobulin G4 (IgG4) monoclonal antibody developed by Regeneron Pharmaceuticals. It acts as an inhibitor of platelet-derived growth factor subunit B (PDGFB), targeting the PDGF signaling pathway implicated in vascular remodeling and disease progression in pulmonary arterial hypertension (PAH). The drug is being investigated primarily for cardiovascular and metabolic diseases, with its lead indication currently being pulmonary arterial hypertension. As of April 2025, REGN13335 has reached Phase 1 clinical trials, where it is administered intravenously or subcutaneously to healthy volunteers to assess safety, tolerability, and pharmacokinetics.

Targets

PDGFB (PDGF-B)

Beyond the preview

Go deeper on regn13335.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on regn13335.

Explore the full profile